Elevated levels of circulating microbial-associated uremic toxins are associated with metastatic duodenopancreatic neuroendocrine tumors in patients with Multiple Endocrine Neoplasia Type 1
Metastatic duodenopancreatic neuroendocrine tumors (dpNETs) are the primary cause of mortality among patients with Multiple Endocrine Neoplasia Type 1 (MEN1). Emerging evidence implicates the microbiome and microbial-derived secreted factors in promoting cancer development and progression. In the current study, we report that the circulating microbial-associated uremic toxins trimethylamine N-oxide (TMAO), indoxyl sulfate (IS), cresol sulfate (CS), cresol glucuronide (CG), and phenol sulfate (PS) are elevated in MEN1 patients with metastatic dpNETs. Proteomic- and metabolomic-based analysis of resected dpNET tissues from MEN1 patients also revealed detectable levels of uremic toxins that positively correlated with peptide-based signatures corresponding to Fusobacterium nucleatum, Faecalibacterium prausnitzii, and Klebsiella pneumoniae and negatively correlated with Streptococcus pneumoniae and Streptococcus thermophilus. A microbial-associated uremic toxin panel (MUTP) was developed and, in an independent case-control validation cohort, the panel yielded an area under the receiver operating characteristic curve (AUC) of 0.94 (95 % CI: 0.85-1.00) with 67 % sensitivity at 95 % specificity for identifying MEN1 patients with metastatic dpNETS. Increases in circulating microbial-associated uremic toxins during early stages of neoplasia were also found to be associated with poor overall survival in an Men1<sup>fl/fl</sup>Pdx1-Cre<sup>Tg</sup> mouse model of MEN1 pancreatic NETs. Our findings suggest that microbial dysbiosis is associated with disease aggressiveness and that increases in circulating microbial-associated uremic toxins may be a prognostic indication for MEN1 individuals who are at risk of having metastatic dpNETs.
Authors
- Ranran Wu (ORCID: https://orcid.org/0000-0002-6276-1425)
- Lee S. Weinstein (ORCID: https://orcid.org/0000-0002-1899-5152)
- Jenny E. Blau (ORCID: https://orcid.org/0000-0002-6725-4262)
- Naris Nilubol (ORCID: https://orcid.org/0000-0002-7348-7804)
- James Welch
- Ehsan Irajizad (ORCID: https://orcid.org/0000-0001-7510-4849)
- Ricardo A. León-Letelier (ORCID: https://orcid.org/0000-0001-7575-0453)
- Gerlof D. Valk (ORCID: https://orcid.org/0000-0001-5841-8344)
- Nancy D. Perrier (ORCID: https://orcid.org/0000-0001-5933-1005)
- Sunita Agarwal (ORCID: https://orcid.org/0000-0002-7557-3191)
- Yining Cai
- Amanda R. Wasylishen (ORCID: https://orcid.org/0000-0002-1940-5169)
- Samir Hanash (ORCID: https://orcid.org/0000-0002-4210-1593)
- Steven Gerard Waguespack (ORCID: https://orcid.org/0000-0003-0280-0100)
- Hiroyuki Katayama (ORCID: https://orcid.org/0000-0003-3117-1390)
- Kim‐Anh Do (ORCID: https://orcid.org/0000-0001-8710-7131)
- Courtney Olsen (ORCID: https://orcid.org/0000-0003-2685-0217)
- Johannes Francois Fahrmann (ORCID: https://orcid.org/0000-0001-5088-0198)
- Carolina R C Pieterman (ORCID: https://orcid.org/0000-0003-4894-373X)
- Jennifer B. Dennison (ORCID: https://orcid.org/0000-0003-3067-0972)
- Mary Walter
- Rachel S. van Leeuwaarde (ORCID: https://orcid.org/0000-0001-6147-9746)
- Mark J C van Treijen (ORCID: https://orcid.org/0000-0003-3853-297X)
- Riccardo Ballarò (ORCID: https://orcid.org/0000-0001-5505-9024)
- Smita Jha (ORCID: https://orcid.org/0000-0001-9201-3340)
- Huiling Liu (ORCID: https://orcid.org/0000-0002-7443-6697)
- Menno R. Vriens (ORCID: https://orcid.org/0000-0002-1225-7896)
Institutions
- National Institutes of Health (US)
- The University of Texas MD Anderson Cancer Center (US)
- University Medical Center Utrecht (NL)
- National Institute of Diabetes and Digestive and Kidney Diseases (US)
- Office of the Director (US)
- Oncode Institute (NL)
- National Cancer Institute (US)
- University of Cincinnati Medical Center (US)
Publication Details
- Journal
- Cancer Letters
- Published
- 2025-02-07
- DOI
- https://doi.org/10.1016/j.canlet.2025.217537
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Cancer Prevention and Research Institute of Texas
- National Cancer Institute